icad (ICAD) Competitors

NeuroPace (NASDAQ:NPCE) and icad (NASDAQ:ICAD) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Is NPCE or ICAD more profitable?

icad has a net margin of -26.63% compared to NeuroPace's net margin of -29.42%. icad's return on equity of -15.03% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-29.42%	-190.84%	-25.08%
icad	-26.63%	-15.03%	-11.77%

Do institutionals and insiders hold more shares of NPCE or ICAD?

78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 24.6% of icad shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by company insiders. Comparatively, 10.3% of icad shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media favor NPCE or ICAD?

In the previous week, NeuroPace had 12 more articles in the media than icad. MarketBeat recorded 14 mentions for NeuroPace and 2 mentions for icad. icad's average media sentiment score of 1.16 beat NeuroPace's score of 0.54 indicating that icad is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	2 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
icad	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings & valuation, NPCE or ICAD?

icad has lower revenue, but higher earnings than NeuroPace. icad is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$79.91M	4.49	-$27.14M	-$0.84	-13.02
icad	$19.61M	5.41	-$5.62M	-$0.19	-20.32

Do analysts rate NPCE or ICAD?

NeuroPace presently has a consensus target price of $15.50, indicating a potential upside of 41.68%. Given NeuroPace's stronger consensus rating and higher possible upside, equities analysts clearly believe NeuroPace is more favorable than icad.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
icad	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more risk and volatility, NPCE or ICAD?

NeuroPace has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, icad has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Summary

NeuroPace beats icad on 9 of the 16 factors compared between the two stocks.